Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. - Wikidata - awgldk - TriplyDB

Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.

Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.

http://www.wikidata.org/entity/Q37292462

about

Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes Advances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized Medicine Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Protein analytical assays for diagnosing, monitoring, and choosing treatment for cancer patients.The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer.Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer.The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue.Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.Breast Cancer Biomarkers: Utility in Clinical Practice.Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer.Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward "precision" cancer therapy.Clinical utility of gene-expression signatures in early stage breast cancer.GENE EXPRESSION PROFILING AND EXPANDED IMMUNOHISTOCHEMISTRY TESTS TO GUIDE SELECTION OF CHEMOTHERAPY REGIMENS IN BREAST CANCER MANAGEMENT: A SYSTEMATIC REVIEW.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation.Developing a new generation of breast cancer clinical gene expression tests Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas.Developments in Ki67 and other biomarkers for treatment decision making in breast cancer.Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer.Amino Acid Transporters and Glutamine Metabolism in Breast Cancer.An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers

P2860

Q26778675-B21AE818-29DF-4C8B-80DA-421BEFA70CF5 Q27001994-E1439EBD-0064-4F83-B466-100F9136472A Q28079118-5435BD98-E5BF-40DE-AC9D-3FEAE8E884E0 Q30432789-E1BE18A2-2CA2-45A1-8635-D4585DAB2E21 Q33544010-000E8FE7-113D-456D-9070-B2C375E861CD Q33745113-C2415DFC-963E-48E3-8874-83C08C6E8F35 Q34171119-70ED427C-57B1-425C-956D-D398A0353C40 Q34173419-B1DE4229-95AC-484B-9ABB-E3CD3850993D Q34577709-E539D980-32B2-45A8-AC59-3FBC770AB6C9 Q34687019-06C0C273-226C-4A59-A19C-9D2468AEA617 Q36462893-653140D7-798B-4632-BB15-7567C1972FB1 Q37031799-207BAD00-9492-4FDE-88CA-15FBF16ABE48 Q37383276-58F2DEB6-31BE-4AC0-94AD-A5495988A2B8 Q37441159-BD5723CB-2C6F-4664-9A4A-9920EA3E4610 Q37495490-C53D90E6-D3EB-4CE3-A3B2-C058FBB950E7 Q37992403-A5DAD1B8-25C8-4E04-9341-092E681A2726 Q38024305-54C423C8-4243-4F83-8B34-86E6BABF98F6 Q38081244-46E4ACAD-3275-4929-B265-2579E0DA041F Q38272730-5E183994-1E74-44E1-B1D4-17BEA3E046F5 Q38754717-7F0649C1-5575-4CB4-86B5-DC71CE81ABC3 Q38795484-5613740A-2B17-44CF-B10C-BD6C03267412 Q39187437-C3EEF621-4425-4099-9E3A-0D9BE29651A8 Q42365301-0E5E92F1-7078-4DB1-B3DC-53DCE4D59BCA Q42737349-535A436F-7361-48D1-92B2-9F414EEAAC7E Q43234010-CCFE66EC-FF42-4DFA-B26D-6633139367BF Q50929945-4831021B-E516-4116-BE42-342F4269D011 Q54481769-919DBFB0-B902-4609-A0F1-C0433D41C3E7 Q54495437-B7DAF939-06BE-48F1-845C-DAB9A528A063 Q54957053-EE51FAD0-B294-4EB4-B6DC-5EAB7994BF8A Q57106403-014BC397-A352-48AA-96B1-F135AB3D7AD8

P2860

Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.

http://www.wikidata.org/entity/Q37292462

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Chemosensitivity and stratific ...... the NSABP B14 and B20 trials.

@en

Chemosensitivity and stratific ...... the NSABP B14 and B20 trials.

@nl

type

label

Chemosensitivity and stratific ...... the NSABP B14 and B20 trials.

@en

Chemosensitivity and stratific ...... the NSABP B14 and B20 trials.

@nl

prefLabel

Chemosensitivity and stratific ...... the NSABP B14 and B20 trials.

@en

Chemosensitivity and stratific ...... the NSABP B14 and B20 trials.

@nl

P1433

Q37292462-A2A5A2D8-212F-4246-BB4F-0EA15D2892D9

P1476

Q37292462-A85938DF-3F4B-4973-ADC5-2ABDC3880E30

P2093

Q37292462-09939A4A-E30E-4F54-B2DC-5EB8B749BBD9

Q37292462-51FD0284-F3C4-400B-B539-7737B083E936

Q37292462-6222CC44-A82E-4278-9FD0-9609A6B5D493

Q37292462-68E4017C-6B87-4FB2-AFB8-37921F65F079

Q37292462-6A4D5959-BB4D-4F02-92EF-715BA58A46F6

Q37292462-7715E40E-1A09-47B3-95CE-50769DF7853A

Q37292462-9ACD072D-DBDA-4F32-9DC1-9DC57C972E1E

Q37292462-A0AB6378-638C-41D6-AE08-56893ABEA07D

Q37292462-ADB73DFC-EC40-4A39-83DF-29237B310065

P2860

Q37292462-05C0611C-5690-46C3-AC80-C89C8988467D

Q37292462-090DDE54-C2E0-4027-B896-02BC262313CF

Q37292462-3E13CC0C-CE3E-481F-A95A-4AEF160DED5E

Q37292462-3E7D382D-9EC9-4605-992F-4D2DDF0B11E0

Q37292462-4C0BAFA7-2FEC-4855-BD11-009B04D96474

Q37292462-57410A3E-3274-4A5A-B85A-C55CE7687846

Q37292462-5EA89F1D-1ED5-4997-9A0E-458902E2291E

Q37292462-6D90E505-A59F-4D2F-8FB0-D587C2509D59

Q37292462-73DEA55A-C12A-4051-AF14-76FEA151BE7B

Q37292462-7A943600-AC31-4BB6-943F-0DD944BE40CA

P304

Q37292462-9BD6DF8C-32C1-45B1-8C29-30F42E985760

P31

Q37292462-B03CEAF6-9219-489E-85E1-E53E9618524E

P356

Q37292462-24A3B6B2-A378-42E0-8C18-103FAAB59FBB

P407

Q37292462-DE81BC3E-54AB-420B-BB49-1275DA52A922

P433

Q37292462-D3D5D9CF-878E-4068-9439-D1F19988C71A

P478

Q37292462-CDAE8970-C7EA-4204-BAE2-B0AC7D714045

P50

Q37292462-0DDD1049-2598-4731-8CDA-18CD06DBFD99

P577

Q37292462-D1D0CBFA-C383-4581-B86D-5836E0EEEF30

P698

Q37292462-ADEC2F47-AAA4-4666-9A34-0CC4138BD9D5

P921

Q37292462-70ACEED0-B824-40F0-B35F-B5B1B850DCB0

Q37292462-A29708B6-E023-4D59-9CF4-B375FD0BE9EC

P932

Q37292462-D8A26F98-A006-439F-AF6D-CA7D3D71EA9D

P356

1078-0432.CCR-08-0647

P1433

Clinical Cancer Research

P1476

Chemosensitivity and stratific ...... the NSABP B14 and B20 trials.

@en

P2093

Brian Z Ring

http://www.w3.org/2001/XMLSchema#string

Chung-Yeul Kim

http://www.w3.org/2001/XMLSchema#string

Gong Tang

http://www.w3.org/2001/XMLSchema#string

Joseph P Costantino

http://www.w3.org/2001/XMLSchema#string

Norman Wolmark

http://www.w3.org/2001/XMLSchema#string

Olga L Bohn

http://www.w3.org/2001/XMLSchema#string

Robert S Seitz

http://www.w3.org/2001/XMLSchema#string

Rodney A Beck

http://www.w3.org/2001/XMLSchema#string

Soonmyung Paik

http://www.w3.org/2001/XMLSchema#string

P2860

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Traditional and newer pathologic factors.

Concordance among gene-expression-based predictors for breast cancer.

Prognostic factors in breast cancer: current and new predictors of metastasis.

Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.

Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.

S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer.

P304

6602-6609

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-0647

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Douglas T. Ross

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18927301

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry

P932

2722068

http://www.w3.org/2001/XMLSchema#string